While there is currently a presence of technology in healthcare, the future holds much more promise, said Allen Lichter, MD, FASCO, senior partner of TRG Healthcare.
While there is currently a presence of technology in healthcare, the future holds much more promise, said Allen Lichter, MD, FASCO, senior partner of TRG Healthcare.
Transcript
How is telehealth allowing community oncologists to reach more patients and improve care?
So, I think, today, telehealth is present in oncology in certain specific areas. Obviously, our imaging colleagues use telehealth to transport images all around the world, and if you go to an emergency department at night, your image is often read in another part of the world, where it’s daylight. Our pathology colleagues are using telecommunications to transmit images. Our patients are sometimes sending images—I certainly sometimes let my dermatologist take a look at certain things on my skin that saves me a trip to the office.
So, we’re touching it. Another area is patient engagement, trying to keep using technology—often an app or a synthetic conversational agent, called a chatbot—to ask the patient how they’re doing, to check up on symptoms, and to allow patients to tell us much earlier about something that’s going on and head it off at the pass and not react to it as a crisis. But the future is going to have so much more. We’re going to have remote sensors. We’re going to be able to monitor physiologic processes. We’re going to be able diagnose and eventually provide therapeutic interventions remotely.
Another area that oncology touches with telehealth is the second opinion process. There are many major institutions and cancer centers that will do second opinions through telemedicine versus having the patient travel for hundreds or thousands of miles.
There’s a presence now, but the future is extremely interesting.
The concept that you or I as patients, the only way we can have an interaction with the healthcare system is to drive to an office or a hospital, wait in the waiting room, go back, get into a gown, and wait for the healthcare provider to come in the room, that’s certainly the paradigm that I grew up in and is the paradigm that predominates in medicine today, but there’s so many ways to deliver effective healthcare. It doesn’t necessarily involve that face-to-face interaction. And believe me, I think face to face in medicine is the essence of medicine. Btu sometimes we need to expand our capacity and to be more convenient and fit into the patient’s life better. That’s where I see us making strides.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More